Determination of the amino acid residues required for the activity of the anti-rhizobial peptide antibiotic trifolitoxin.
OBJECTIVE
The first aim was to determine those amino acid residues required for the biological activity of the potent peptide antibiotic, trifolitoxin (TFX). The second aim was to determine the concentrations of TFX1 and TFX2 that cause 50% inhibition of bacterial growth (Ki), the two predominant isomeric forms of TFX made by Rhizobium.


RESULTS
Site-directed mutagenesis of tfxA was used to produce strains that made mutant TFX peptides. The mutant tfxA genes were placed on a vector and inserted in Rhizobium leguminosarum b. trifolii Tn54A112, a tfxA mutant of strain T24 that lacks trifolitoxin activity. Our standard bioassay was used to assess the activity of these mutants. TFX1 and TFX2 were purified by reverse phase chromatography. Several concentrations of each peptide were assayed for biological activity to determine Ki. The unmodified TFX peptide (DIGGSRQGCVA) was synthesized and was found to lack any biological activity. Four of the 11 amino acid residues in ribosomally synthesized, post-translationally modified peptide were required for TFX activity. These required amino acids include arginine (R37), glutamine (Q38), glycine (G39) and cysteine (C40). S36T and S36Y mutants showed reduced TFX activity. The numbering system is based on the 42-amino acid TfxA peptide that is post-translationally modified to form the active TFX peptide. The Ki of TFX2 was determined to be 10-fold lower than TFX1.


CONCLUSIONS
The post-translational modifications of the TfxA peptide are required for biological activity. TFX2 is far more active than TFX1.


CONCLUSIONS
The sequence of the TfxA peptide appears to have been optimized for maximum activity through the course of evolution. Even conservative changes to any of the amino acid residues required for activity results in a complete loss of activity. The understanding of the action of this peptide is critical for its proposed action as a control agent for crown gall disease.
Department of Bacteriology, University of Wisconsin-Madison, Madison, WI, USA.
A J
AJ
Scupham
E W
EW
Triplett
D000596:Amino Acids / Q000032:analysis*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001430:Bacteriocins / Q000494:pharmacology*; D005798:Genes, Bacterial / Q000235:genetics; D007536:Isomerism; D016297:Mutagenesis, Site-Directed / Q000379:methods; D009154:Mutation; D010446:Peptide Fragments; D010455:Peptides / Q000032:analysis / Q000494:pharmacology*; D016961:Rhizobium leguminosarum / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D013329:Structure-Activity Relationship
D000596:Amino Acids; D000900:Anti-Bacterial Agents; D001430:Bacteriocins; D010446:Peptide Fragments; D010455:Peptides; C081619:trifolitoxin